Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
INSIDER PURCHASE / SYNDICATE
KALV - 10% OWNER Venrock Healthcare P 86,048 $14.618
Boom!
Killed it with puts today!
* * $KALV Video Chart 02-09-2021 * *
Link to Video - click here to watch the technical chart video
? lol
Profitability
Profit Margin 0.00%
Gross Profit (ttm) $-27.5M
EBITDA $-48.38M
Net Income Avi to Common (ttm) $-37.12M
Diluted EPS (ttm) -2.08
Book Value Per Share (mrq) $3.63
Going to keep diluting more and more
They are hemorrhaging money. Have pretty much zero revenue. They still have hundreds of millions to spend of your money until phase 3 and beyond.
Operating Margin (ttm) -905.50%
Management Effectiveness
Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%
Revenue $5.4M
Revenue Per Share $0.30
News: $KALV KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr...
Find out more https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-appoints-daniel-b-soland-to-board-of-directors-8035190.html
News: $KALV KalVista Pharmaceuticals to Present at Needham Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, a...
Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-to-present-at-needham-healthcare-conference-7939130.html
News: $KALV KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosi...
Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-7846828.html
$15.50 now ~ keep rollin
$KALV
The way this is dropping, there has to be a lawsuit over the sale of cash at 60% off.
Where are those ambulance chasing securities lawyers?
CBYL is now KALV with a 1:14 reverse stock split.
Be very careful for the next few days as until all or most of the CBYL shares are converted to KALV, the only sellers will be private Kal Vista investors, those who bought after the symbol change and professionals. The price is likely to be high until existing CBYL retail holders can sell their shares. In addition, the existing CBYL shares will only represent 20% of the O/S. 80% will be held by the private investors in KVAL.
WOW - look at this $0,89---> $4,60
New Ticker name now : KALV
look at NASDAQ - PM
Apparently the merger deal was approved by a huge margin.
Still don't get it.
* * $CBYL Video Chart 11-21-16 * *
Link to Video - click here to watch the technical chart video
CBYL continuing its upward momentum pre-market.
* * $CBYL Video Chart 11-18-16 * *
Link to Video - click here to watch the technical chart video
Oh okay. Im still up for it even if it is a merger. Good thing volume picked up today.
New buyer? They're not being bought, they're merging with another company and selling their cash at a steep discount.
Maybe the large shareholders decided it's better to take a smaller loss now by liquidating, than wait for a larger loss later and they're voting against the deal.
I can only hope!
Somethings fishy going on here. Why the sudden spike in volume? New buyer in sight?
Fun while it lasted.
$700k / month for a company that has only a few execs and no business left???
No wonder they want to merge. If they liquidate, the execs all lose their gravy train.
Maybe that can be part of the class action suit.
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
Sadly, I don't think so.
Any idea what the general consensus among shareholders is? We gonna be able to block this merger or is a 'no' vote futile?
LOL, CBYL declined back to $0.49 again! The next two supports are $0.4505 and $0.4401.
Let' see if that very sick merger deal still goes through...
Anyway the planned big Reverse/Split (1:14) should kick in very soon unless we all vote against it!
Can you please stick that post#376 to the CBYL board? Thanks in advance! We all should call the company and let them merge with TNXP to protect our interests in CBYL! It will be the best deal for both Debt-Free and High BV & CV Bio-Tech NASDAQ companies!
Anyway CBYL is up 5.6% so far! $0.4984 seems the New bottom support! Hopefully it will test last week's highs area $0.544 ~ $0.54 again before the end of today...
Now CBYL has Three strong supporting price $0.4401, $0.4505, and $0.475!
Who are those very stupid sellers which put 88K shares at $0.60 and over 130K shares at $0.65?
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
432
|
Created
|
04/24/15
|
Type
|
Free
|
Moderators |
KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need. KalVista has built an expanding clinical and advanced preclinical product pipeline targeting multiple routes of administration to treat these diseases.
KalVista’s initial focus is on advancing a portfolio of orally delivered plasma kallikrein inhibitors for the treatment of HAE. The most advanced program, KVD818, is in Phase I clinical studies and additional molecules are expected to reach the clinic in 2017. KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor, has successfully completed its first-in-human study in patients with DME and is being prepared for Phase 2 clinical studies.
KalVista has an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.
KalVista has offices in Cambridge, MA, USA and Salisbury, UK.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |